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Introduction
Community-acquired meningitis is associated with high
morbidity and mortality. The epidemiology of community-
acquired meningitis has changed over the past 15 years
with the use of new vaccines and with the development of
resistance to antibiotics. Bacterial meningitis would appear
to be the most frequent by far, but most viral aetiologies
are very often poorly recognized. The annual incidence of
purulent community-acquired meningitis in France was
estimated at 22 cases per million inhabitants in 1993. Age
is a major risk factor in bacterial meningitis. The most
affected group is children under 2 years of age, in whom
the infection rate ranges from 10 to 110 cases per 100000
infants per year. Such cases must be considered as an
absolute medical emergency. This review is limited to
meningitis in immunocompetent patients.
Bacterial epidemiology
From birth until the first month of life, Streptococcus
agalactiae, Listeria monocytogenes and Enterobacteriaceae
(especially  Escherichia coli) are the main pathogens. From
2months until 4years of age, meningitis is principally due
to Haemophilus influenzae type B (the incidence of which is
dramatically decreasing because of widespread vaccina-
tion), Neisseria meningitidis and Streptococcus pneumoniae. In
children, teenagers and young adults, N. meningitidis and
S. pneumoniae represent more than 80% of the cases.
Above the age of 60 years, S. pneumoniae and H. influenzae
are the most frequently isolated bacteria [1,2].
When all of these bacteria are taken together, the ele-
ments that indicate a poor prognosis are as follows: age
less than 1month or greater than 45years; worsening level
of consciousness on admission; and forms with purpura
fulminans [3–6]. In the absence of a specific treatment,
purulent meningitis is ultimately fatal.
Pneumococcal meningitis
Pneumococcal meningitis is the most frequent cause of
bacterial meningitis in those older than 30 years, and was
responsible for 20% of cases of purulent community
meningitis in children and 60% of adult cases in France in
1993. It is also more severe in terms of mortality (15–30%)
and morbidity (deafness).
The increasing resistance of S. pneumoniae to penicillin (in
more than 10% of isolates) has created a problem for
therapy, which at present cannot be completely optimized
and requires a knowledge of the sensitivity phenotype of
the bacteria in question. Penicillin-resistant pneumococci
(PRP) include pneumococci with an intermediate sensi-
tivity [minimum inhibitory concentration (MIC) of
between 0.12 and 1mg/l] and highly resistant pneumo-
cocci (MIC >1mg/l).
Resistance to b-lactams is related to modifications of the
genes coding for penicillin-linked proteins (PLPs), which
are the active sites for all b-lactams, especially PLP2b and
PLP2x [7]. Such genomic change is due either to a
genetic transfer or to on-off mutations. The main
serotypes involved in the resistance to b-lactams are 6A,
6B, 14, 19A, 19F and 23F, and 99% of the serotypes are
present in antipneumococcal vaccine of 23 valences. This
evolution in resistance should lead to a renewed interest
in antipneumococcal vaccination.
Resistance to b-lactam antibiotics in pneumococci has been
increasing in a disturbing manner, especially in Europe.
The first strains resistant to penicillin were described in
Boston in 1964 and in Chicago in 1974, and the first case of
pneumococcal meningitis resistant to ceftriaxone was
reported in 1991. The progression of resistance has been
constant in the USA; from 1979 to 1987 the rate of resis-
tance was below 10%, but since 1987 there has been an
increase of up to 30% in PRP. In Europe, Spain has a rate of
almost 60% of PRP, followed by Bavaria with 50% resis-
tance, but the rate is lower for the rest of Germany. France
is next with 36% in children and 25% in adults in 1994. The
magnitude of resistance was high in half of the cases.
Among the cephalosporins, cefaclor, cefuroxime and
cefixime are no longer active on strains resistant to
PRP = penicillin-resistant pneumococci; MIC = minimum inhibitory concentration; PLP = penicillin-linked proteins; CSF = cerebrospinal fluid;
TNF = tumour necrosis factor; IL = interleukin; CT = computed tomography.penicillin, and a direct relationship has even been noted
between cefaclor and penicillin resistance. Of PRP strains
10% are cross-resistant to macrolides: erythromycin, as
well as clarithromycin and azithromycin.
In children, the risk factors for acquiring infection with
resistant S. pneumoniae are hospitalization, living in closed
populations, b-lactam treatment in the preceding months
and recurring otitis media. In adults the risk factors are
immunodeficiency, nosocomial infections and b-lactam
treatment in the preceding months. Limiting the spread of
S. pneumoniae resistance to antibiotics therefore depends
on the following: more rational utilization of antibiotics
and perhaps reduction of the systematic prophylaxis of
acute otitis media in children with recurrent otitis; evalua-
tion of the optimal duration of antibiotic therapy; evalua-
tion of posologies and the intake required in order to avoid
long periods with serum levels nearly at subinhibition con-
centrations and favouring the selection of resistant
mutants; alternating different classes of antibiotics; and
development of the antipneumococcal vaccine.
Meningococcal meningitis
Meningococcal meningitis occurs in endemics, with cases
that are usually sporadic causing minor endemia that are
limited in time and space, particularly in closed popula-
tions of children and young adults. There is a distinct pre-
ponderance of group B (60%) over group C (30%)
organisms. The mean mortality rate of 10% is principally
linked to the occurrence of purpura fulminans [8].
Haemophilus influenzae meningitis
Widespread vaccination is currently disrupting the epidemi-
ology of H. influenzae meningitis, which is caused by type B
strains. Approximately 50% produce b-lactamases, making
them resistant to amino-penicillins. Despite this increase in
resistance, the mortality rate has gone from 10 to 3%.
Physiopathology
The bacteria responsible for purulent meningitis are of
the extracellular multiplication type, and have properties
that make them resistant to nonspecific defence factors
and allow them to develop in the host tissues. They also
have specific properties that enable them to invade the
meninges and cause inflammation [9,10].
Bacterial penetration in the cerebrospinal fluid
There are various arguments that support the hypothesis of
penetration of bacteria into the cerebrospinal fluid (CSF)
by the haematogenous route, with secondary penetration
through the haematomeningeal barrier. In the case of
experimental infection with H. influenzae, rhinopharyngeal
administration of bacteria is followed by bacteremia and
then invasion of the CSF. Similarly, intraperitoneal injec-
tion of N. meningitidis in newborn rats or intravenously in
macaques causes secondary colonization of the CSF [11].
The haematomeningeal barrier is only one of the ele-
ments of the haematoencephalic barrier, and pathogenic
bacteria are hypothesized to invade the CSF via the blood
by two different routes: direct penetration of the
meningeal capillary endothelium; or by direct penetration
at the level of the choroid plexus, which produces CSF by
secretion. The latter of these would appear to be the most
plausible hypothesis following postmortem and experi-
mental observations of major and selective concentrations
of bacteria in the choroid plexus capillaries.
Inflammatory mechanisms of the subarachnoid space
Once the bacterium has invaded the CSF, little can
prevent it from multiplying because there is almost no
complement fractions and the immunoglobulin concentra-
tion is very low. On the other hand, poor nutrition slows
bacterial multiplication.
In order to understand the cascade of events that occurs as
soon as the bacterium has invaded the CSF, experimental
meningitis models have been designed by direct injection
of bacteria into rabbit and rat cisterna magna, making it
possible to short-circuit the haematomeningeal barrier.
In-situ production of cytokines
The most important event that follows bacterial penetra-
tion into the CSF is the production of cytokines [12]. In
animal experiments, intracisternal injection of lipopolysac-
charide triggers production of tumour necrosis factor
(TNF)-a, interleukin (IL)-1 and IL-6, preceding the
appearance of inflammatory exudate, which can be par-
tially prevented by the injection of anti-TNF-a and/or
anti-IL-1 antibodies. Injection of TNF-a and IL-1 into
the cisterna magna is followed by an elevation in the
protein concentration in the CSF, an afflux of polynuclear
cells and an increase in the weight of the brain, reflecting
oedema. It would therefore follow that the production of
cytokines in the CSF is a prerequisite to episodes of
meningitis. This production occurs in situ, is independent
of all systemic cytokine production because the molecules
cannot penetrate the haematomeningeal barrier and there-
fore comes from the macrophage cells within the
meninges itself [13,14].
Polynuclear afflux
Cytokine release allows for recruitment of polynuclear
cells in the CSF by an adhesion phenomenon between the
neutrophils and the endothelial cells. In fact, TNF-a and
IL-1 induce the expression of adhesion molecules at the
surface of the endothelium that favours loose adhesion of
polynuclear cells and their rolling on the endothelial
surface. Under the influence of IL-1, the endothelial cell
produces IL-8, which leads to the detachment of the
polynuclear L-selectin and interrupts polynuclear rolling
because of the increase in integrin activity. These phe-
nomena provide for even tighter adhesion between the
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clear extravasation in the infected tissue [15,16].
Alteration of the haematomeningeal barrier
The other consequence of cytokine production is a reduc-
tion in the tightness of the hematomeningeal barrier,
which is essentially related to local production of IL-1 and
synergistically assisted by TNF-a, creating a loosening of
the tight cerebral capillary junctions.
Consequences of bacterial meningitis
All of the events that occur during an episode of bacterial
meningitis are the result of polynuclear afflux and alter-
ation of the haematomeningeal barrier. The result is a
mixed cerebral oedema (ie both interstitial, because it is
linked to the resorption of CSF at the level of the arach-
noid villi, and vasogenic, because it is linked to an increase
in the permeability of the haematomeningeal barrier). In
addition, this major meningeal inflammation can lead to
major vascular alterations of the meningeal vessels, as
occurs in vasculitis, facilitating microthromboses and par-
ticipating in profound alterations in cerebral blood flow
and anoxia [17].
Meningococcus
N. meningitidis is a Gram-negative, oxidase-positive aerobic
diplococcus that has a polysaccharide capsule. It is a sapro-
phyte, and colonizes most humans at some point in their
lives without producing any particular symptoms. The
development of disease after exposure to meningococci is
the result of a poorly known mechanism of host factors
that have an influence on bacterial invasion of mucosal
surfaces. Among the elements that influence host
response, genetic control of the response to the acute
stage and cytokine secretion (TNF-a, IL-1, IL-6) is of
importance in making the prognosis. Moreover, a defi-
ciency in complement predisposes the patient to a
meningococcus infection with unusual serogroups (X, Y,
Z, W135, 29E) [18,19].
Listeria monocytogenes
L. monocytogenes is an occasional intracellular Gram-posi-
tive bacteria that is capable of multiplying in the
macrophages and in most of the cells of the infected host
tissue. From the sites of intracellular multiplication, L.
monocytogenes can spread through the blood and reach
numerous target organs, particularly the placenta and the
central nervous system. The bacterium first enters via
direct contact with the host cells through an 80kDa
protein called internalin, coded by chromosomal gene
InlA. Internalin is a protein located at the surface of the
bacterium and has a structural organization that is charac-
teristic of numerous Gram-positive bacteria proteins (such
as Streptococcus and Staphylococcus spp.). Internalin interacts
with receptors of unknown nature (probably integrins)
located at the surface of the infected cells. After penetrat-
ing the cells, the bacteria are capable of escaping the
phagosomes and of multiplying in the cytoplasm. In the
infected host, orally ingested bacteria go through the
intestine via Peyer’s patches and reach the lymphatic gan-
glions and the blood circulation. The principal target
organ is the liver, where the bacteria multiply inside the
hepatocytes. Hepatocyte lysis induced by the early
recruitment of polynuclear cells triggers a liberation of
intercellular bacteria and results in prolonged bacteraemia.
At this stage, the disease is often managed well by
immunocompetent patients, who may contract an infec-
tion that is often totally asymptomatic. This is probably
the most frequent scenario if the frequency of exposure to
L. monocytogenes is low. However, if the inoculum is
massive, in a pregnant woman, or in patients who are
immunocompromised (patients with acquired immunode-
ficiency syndrome, patients with neutropenia or who are
undergoing chemotherapy) or who present with hepatic
anomalies (cirrhosis, hemochromatosis), infection of the
hepatocytes is not controlled and the bacteria are released
into the bloodstream. Metastatic localizations are possible
at this stage, particularly in the placenta or the central
nervous system [20].
Therapeutic implications
Bacterial meningitis is an infection of a defined space in
which the host is compromised because of the absence of
complement fractions and the low levels of specific anti-
bodies. For this reason phagocytosis is ineffective and bac-
terial multiplication is rapid. Optimal antibiotic treatment
requires that the selected antibiotic has a bactericidal
effect in the CSF.
Passage of antibiotics into the cerebrospinal fluid
Antibiotics that strongly bind to proteins and those with a
high molecular weight diffuse poorly into the cerebral
parenchyma and the CSF. Meningeal inflammation par-
tially improves this situation by modifying the permeabil-
ity of the haematomeningeal barrier (increase in vesicular
transport, and separation of the tight junctions between
the endothelial cells and the meningeal vessels) [21].
Antibacterial synergy in cerebrospinal fluid in vivo
In a model of L. meningitis infection, an ampicillin–gentam-
icin combination (in vitro synergy) turned out to be more
rapidly bactericidal than either when used alone [22].
Antibiotic concentration in the cerebrospinal fluid
Spinal concentrations of antibiotics that are equal to the
minimal bacteriostatic concentration of a bacteriostatic
drug or to the MIC of a bactericidal drug should be effec-
tive. This was not the case in an E. coli meningitis model,
however, in which concentrations greater than 10 times
the MIC were required to obtain the maximum elimina-
tion rate for CSF bacteria. The need to obtain spinal con-
centrations superior to 10 times the MIC has also been
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One explanation could be that infected CSF reduces
antibiotic activity. For example, the low pH of infected
CSF (between 6.7 and 7.1) reduces the activity of amino-
glycosides and the increase in protein concentration
decreases the concentration of the active drug, particularly
that of the strongly bound b-lactamase (cephalosporins).
This implies the use of high doses of antibiotics, espe-
cially when the MIC is elevated.
Immunotherapy
Because of the excessive inflammation of the meningeal
spaces and its experimental aggravation by bacterial lysis
caused by the antibiotics, it can be useful to modify the
various players in this immunoinflammatory cascade by
attempting to inhibit the polynuclear interactions with the
haematomeningeal barrier. Inflammation, however, plays
a positive role in the penetration of certain antibiotics at
the infection site. The use of methylprednisolone reduces
the spinal penetration of ampicillin and gentamicin by
approximately half.
Diagnosis
Clinical diagnosis
The infectious syndrome is always present. It has a brutal
aspect with a high fever (>38.5°C), shivers and myalgia,
sometimes accompanied by the following: pneumopathy
(in cases of pneumococcus infection), purpura and septic
shock. At times, it is subtle and is unfortunately diagnosed
as an ear–nose–throat infection, which are often degener-
ated by antibiotic therapy.
The meningeal syndrome is quasi constant. Cephalalgia is
diffuse, intense and continuous, and can radiate towards
the nape of the neck and the back. It is increased by light,
noise and coughing. Vomiting is frequent.Meningeal stiff-
ness corresponds to the extension of the neck muscles
during massive flexion of the head. It is responsible for
the coiled position. It can sometimes be subtle, especially
in an early stage or in elderly patients or in cases of coma.
It can be evaluated by means of certain manoeuvres.
Kernig’s sign is a symptom of meningitis that is demon-
strated when patients cannot keep their legs extended
while sitting on a bed. In the prone position, the patient
cannot raise and extend his arms because flexing occurs at
a certain height. Brudzinski’s sign is a spontaneous flexion
of the thighs and legs during flexion provoked by the head
(when the neck is flexed from a supine position). The
meningeal syndrome can also include signs of cutaneous
hyperesthesia or pyramidal irritation such as in osteoten-
don hyperreflexia.
Signs of encephalitis are erratic but must be considered as
having a poor clinical outcome; they include change in
mental status that ranges from mental confusion to coma.
They may also include local or generalized convulsions.
The factors that should raise suspicion of certain aetiologic
diagnoses are listed Table 1.
Biological diagnosis
Lumbar puncture
When the clinical examination only reveals meningeal and
infectious signs (60–70% of cases) lumbar puncture is the
first examination to perform [23]. If, on the other hand,
onset is progressive and there appears to be signs of defi-
ciency without change in mental status, followed by signs
of intracranial hypertension, a cerebral computed tomogra-
phy (CT) scan must be urgently performed in order to
exclude the presence of an expansion process. Fundus-
copic examination is completely useless.
In cases of comatose meningitis, the relationship between
lumbar puncture and herniation is, in any case, very debat-
able. Such an important examination should therefore not
be put off.
Macroscopically, the CSF has an elevated opening pres-
sure, is cloudy (rice water) or purulent, confirming puru-
lent meningitis and the need for subsequent antibiotic
therapy (Fig. 1). Cytochemically, the CSF contains
numerous polynuclear neutrophils (³1000/mm3); protein
concentration is high (³1g/l); and the CSF glucose con-
centration is low or even collapsed but, in any case, is less
than 70% of the blood glucose concentration (ie the
CSF:blood glucose concentration ratio is <0.3).
Particular forms can be encountered. The CSF can have
minimal cytochemical modifications but be swarming with
bacteria in cases of fulminant meningococcus meningitis,
necessitating Gram’s staining in all cases with purpura,
whatever the cytological results of the CSF. Moreover, an
R58 Critical Care 1999, Vol 3 No 4
Table 1
Aetiologic diagnoses and suggestive features
Aetiology Suggestive features and comments
Streptococcus Severe alcoholism, hypogammaglobulinemia,
pneumoniae neutropenia, drepanocytic anemia, splenectomy,
polynuclear function deficiency, suppressive
immunological therapy, acquired duramatral
breach
Neisseria Complement deficiency must be suspected.
meningitidis However, there are no real risk groups.
Classically, epidemics occur in closed
populations of young adults.
Listeria Extremes of age, pregnancy, hepatic cirrhosis, 
monocytogenes haemochromatosis, chronic renal failure, cellular 
immunodeficiency (Hodgkin’s and non-
Hodgkin’s lymphoma, chronic lymphoid 
leukaemia, corticotherapy, organ transplantation)intense cellular reaction without micro-organisms on
direct examination is possible, with bacteriologic confir-
mation by culture of CSF.
Lymphocytosis is possible if lumbar puncture is per-
formed very early, but this condition above all indicates
Listeria meningoencephalitis [24,25].
Blood cultures
Blood cultures provide an indispensable diagnostic com-
plement. Nonspecific examination results such as polynu-
cleosis and elevated C-reactive protein may be suggestive
of a bacterial aetiology.
Bacteriology
Gram’s staining will provide an aetiologic diagnosis in
60–90% of the cases of bacteriologic meningitis. The per-
centage of positive direct examinations is highest for
S. pneumoniae and  H. influenzae, is lower for N. meningitidis,
and is especially low for L. monocytogenes. Culturing is sys-
tematic and allows for isolation and identification of the
causative bacteria. An antibiogram may be directly per-
formed with the CSF if it is sufficiently rich in bacteria.
The results obtained after 18–24h must always be con-
firmed by classic study performed after the culture. In
cases of pneumococcus infection, resistance to b-lacta-
mases is sought by means of an oxacillin disk. Detection is
completed by parallel determination of the MIC, per-
formed either using classic dilution methods or using E-
test with penicillin G and the b-lactams habitually used
for the treatment of pneumococcus meningitis.
In patients with H. influenzae infection it is essential to
look for b-lactamase production. Some strains of N. menin-
gitidis with reduced sensitivity to penicillin G have been
observed in France and Spain, but without therapeutic
consequences (at the time of writing).
The interest of soluble antigen exploration has been
subject to diverse evaluations. Performed using a particle
agglutination of latex sensitivity technique, it can rein-
force a diagnosis when the Gram’s staining is question-
able, but is of little use when the Gram’s staining is
negative [23]. Polymerase chain reaction can be a better
means to detect bacteria in the CSF. Intraspinal lactate
concentration alone does not have sufficient diagnostic
value [26].
During the initial work-up, the diagnosis of bacterial
meningitis is confirmed if the bacteriologic examinations
are positive. In the case of negative results on direct exam-
ination, the medical probabilities should be determined in
order to differentiate the bacterial or viral nature of an
episode of meningitis. This can be achieved by using valid
decision models that take several cytological and biochem-
ical parameters of the CSF into account, in addition to the
clinical data. Subsequent biological examinations are dic-
tated by the clinical evolution and the initial bacterial
data. A possible second lumbar puncture is performed
36–48h after treatment, enabling the clinician to judge the
therapeutic efficacy of CSF sterilization, as well as the rise
in glycorrhachia. The other cytological and biochemical
parameters of the CSF are of no diagnostic or prognostic
value. In cases of therapeutic failure, an antibiotic may be
administered in the CSF.
Radiological examinations
The indications for scanning or imaging should be very
limited when a patient with purulent meningitis is admit-
ted. Performing a CT scan before the lumbar puncture
exposes the patient to the risks of delaying an antibiotic
therapy that has reliable results. Lumbar puncture must
therefore precede a CT scan, even in cases of coma. This
diagnostic approach should only be changed if there are
localized neurological signs that suggest another diagnosis
or if there is a risk of an intracranial complication, possibly
making lumbar puncture dangerous. Haemocultures and
antibiotic therapy must therefore be immediately under-
taken before imaging results are obtained (Fig. 1). In an
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Figure 1
Management algorithm in case of suspicion of bacterial meningitis.
Directed
antibiotherapy
Suspicion of bacterial meningitis
Localized neurological deficit
Absent Present
Blood cultures
Blood cultures
Lumbar puncture
Empiric antibiotic therapy
Positive Gram staining
or
positive antigen test
No Yes
Cerebral computed
tomography scan:
No lesion: lumbar puncture
Lesion: abscess, empyema
Empiric
antibiotherapyemergency situation, cerebral CT scan enables the clini-
cian to resolve most diagnostic problems. Magnetic reso-
nance imaging is more accurate than CT, but it is less
often available and does not provide decisive supplemen-
tary information.
Once antibiotic therapy has been started, the diagnosis of
intracranial complications will depend on imaging. Cere-
bral CT scan is adequate for most intracranial complica-
tions (hydrocephalus, abscess, empyema, cerebral infarct,
haemorrhage, ventriculitis). However, in cases of cerebral
thrombophlebitis CT scanning does not reveal direct signs
and an angiography is required. Magnetic resonance
imaging is the examination of choice when it is available
and will provide a diagnosis of all intracranial complica-
tions with sensitivity and specificity that are superior to
those of CT scanning, particularly for the diagnosis of
cerebral thrombophlebitis. In infants, transfontanel ultra-
sonography is easy to perform and enables the clinician to
detect abscess, ventriculitis and hydrocephalus.
A search for a portal of entry is especially justified in
pneumococcal meningitis. Portals of entry are often
ear–nose–throat-related in cases of both acute and chronic
pathology. Imaging relies on CT scanning, which has
better bone definition than MRI. It is not indicated for
clinically diagnosed acute otitis. On the other hand, it is
justified when mastoiditis or an unsatisfactory evolution of
meningitis is suspected.
Imaging is indispensable for the preoperative work-up of
all chronic pathologies and for the diagnosis of most cases
of acute sinusitis.
The existence of an osteodural breach must be considered
in cases of post-traumatic pneumococcal meningitis and
recurring meningitis. In rare cases, the breach can be a
congenital ear and petrosa malformation that is clearly
revealed by CT scan, or an anterior meningoencephalo-
cele or lumbosacral dermic sinus, which are better
explored using magnetic resonance imaging. More often,
the breach is secondary to a recent or old head trauma or
to surgery at the base of the skull. At the level of the ear,
exploration for a breach must be performed by CT scan-
ning in frontal and axial millimeter sections. For the ante-
rior floor, the CT scan should be used to investigate for a
lack of continuity, essentially at the level of the lamina
cribrosa and the roof of the ethmoid bone. CT scanning is
the technique of choice because it best examines the
small bone dehiscences. Isotropic transit of the CSF is no
longer an indication [23].
Differential diagnosis
Atypical cerebrospinal fluid
It can be difficult to differentiate between bacterial menin-
gitis “beheaded” by an antibiotic treatment and viral
meningitis which is diagnosed early due to the context,
briefness of the signs and normal glycorrhachia, reinforced
by the disappearance of polynucleosis and the appearance
of lymphocytosis in the CSF sampled 24–48h later.
In the absence of bacterial meningitis, the presence or
even the predominance of polynuclear cells in the CSF
can be encountered in several situations: bacterial patholo-
gies suppurated from the brain or parameningeal spaces
(subdural empyema, brain abscess), fungal infections
(cryptococcosis, candidiasis, histoplasmosis, coccid-
ioidomycosis), rare cases of amoebic meningitis, neoplastic
meningitis, chemical meningitis (co-trimoxazole, nons-
teroidal anti-inflammatory drugs, azathioprine), systemic
recurrent aseptic puriform meningitis, disseminated lupus
erythematosus, sarcoidosis, Behçet’s disease. Rupture of
an epidermoid cyst in the arachnoidea space and Mol-
laret’s benign recurrent pleocytic meningitis are very rare
and their diagnosis is favoured by recurrence with a
sudden onset, rapidly favourable evolution and the poly-
morphic character of the CSF.
Acute clear cerebrospinal fluid meningitis
Acute clear CSF meningitis is benign in most cases. It is
due to a great number of viruses and evolves sponta-
neously towards resolution. Measles and German measles
are in very distinct decline due to systematic vaccination.
The major problem is the possibility of a herpetic aetiology
leading to emergency empiric treatment with acyclovir.
The other emergency diagnostic hypothesis is Listeria neu-
romeningeal infection, which also requires emergency
empiric antibiotic treatment. The possibility of a tubercu-
lous infection should not be ignored, but therapy is often
less urgent. The various diagnostic hypotheses are often
formulated from the epidemiological data gathered from
the context, because the microbiological results often
arrive too late for emergency treatment [9].
Herpetic meningoencephalitis
Herpetic meningitis is usually due to herpes simplex virus
I. In 30% of the cases, the encephalitis is primary, but in
70% it is preceded by a past history of benign herpes.
Such pathology represents direct viral aggression located
at the frontal and temporal level and leading to necrosis of
the affected tissue. The clinical picture is not very spe-
cific, but the patient will present with increasingly severe
mental confusion, convulsions, cranial nerve impairment
and olfactory hallucinations. However, because these
symptoms will appear too late for effective treatment, her-
petic aetiology must be presumed for encephalitis. If
untreated, death occurs in 60–80% of the cases with very
severe neurological sequelae in the surviving patients.
Biological diagnosis is difficult to perform: the CSF is
lymphocytic and serum antibodies are of little use for an
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tion (estimated by comparing its level with serum level) is
specific but inconsistently detected. The electroen-
cephalograph is more reliable with pseudo-periodic rhyth-
micity in the frontotemporal regions. However, this
assessment is often delayed in comparison with therapy, the
need for which is urgent; its absence must not delay antivi-
ral treatment. The same is true for the cerebral CT scan
with iodine injection. The images are typically hypodense
zones with peripheral contrast in the temporal and frontal
regions. Such images are often bilateral and symmetrical.
The currently accepted treatment for herpetic encephali-
tis has considerably improved outcome: acyclovir,
10mg/kg every 8h by intravenous infusions of approxi-
mately 1h. The duration of treatment is classically 10days,
but there have been reports in the literature of rare
relapses due to a short duration of therapy, and conse-
quently 3weeks of treatment are often recommended.
Listeria meningoencephalitis
Listeria meningoencephalitis is certainly the most fre-
quently encountered at present. The clinical signs are not
very specific. It is, however, possible to stress the frequent
association of a straightforward meningeal syndrome and
impairment of one or several cranial nerves. Diagnosis is
confirmed by isolation of the bacterium in blood cultures
and/or CSF culture. Given the small size of this Gram-
positive bacillus and the low inoculum, direct examination
of the CSF is very often negative. The cytorachia is typi-
cally mixed with polynuclear cells and lymphocytes, but a
predominantly lymphocytic composition is observed just
as fequently. Cerebral CT scan will reveal diverse features
ranging from simple oedema to necrosis. On the other
hand, a temporal lesion location is suggestive. Encephali-
tis is diffuse when there are intracerebral abscesses pre-
dominantly located in the rhombencephalon with multiple
and necrotic abscesses. More rarely, there can be pure
encephalitic forms without meningitis, which must be
treated as an emergency (see the section on antibiotic
therapy for L. monocytogenes, below).
Such impairment of the central nervous system is singular.
Although it is frequently observed with a virus, it is rarely
encountered with pathogenic bacteria, except Mycobac-
terium tuberculosis meningoencephalitis and rare neu-
romeningeal infections with Nocardia asteroides, or Brucella
or  Leptospira spp. Certain parasites such as Toxoplasm
gondii are also capable of triggering very severe encephali-
tis, especially in acquired immunodeficiency patients.
Tuberculous meningoencephalitis
Neurological locations account for 0.5% of the cases of
tuberculosis. It should nevertheless be considered when
the predisposing factors suggest it (disadvantaged social
background, recent immigrant, tuberculosis in family
circle) or when neurological impairment is not sensitive to
antibiotic or antiviral therapies. Diagnosis is difficult: the
CSF reveals a mixed composition (but could be lympho-
cytic), hypoglycorrhachia and hypochlorurorachia (but can
be normal), hyperproteinorachia (which only expresses
the chronic inflammatory aspect); the growth of M. tuber-
culosis (Koch’s bacillus) is slow and cannot support a rapid
diagnosis; and direct examination of the CSF by Ziehl
staining is exceptionally positive. There is hope with the
detection of bacterial antigens in the CSF (using a gene
amplification technique, polymerase chain reaction), but
this is still in the research stage and is not routine. Cere-
bral imaging is only useful in cases with localized lesions:
abscess or evolved tuberculoma, or granulomas that are
difficult to detect. Apart from these cases, the images are
less specific and show inflammation: oedema or inflam-
matory filling of the cisterna. More often than not, the
clinician is therefore reduced to prescribing a presump-
tive therapy following a series of arguments, which can
easily lead to therapeutic failure.
Evolution and prognosis
In the review by Durand et al [3] of 493 cases of bacterial
meningitis in adults the mortality rate was 25%, and in a
recent study of Gram-negative meningitis 61% of the chil-
dren had neurological sequelae [27]. Predisposing factors
and signs of severity for meningitis caused by several aeti-
ologic agents are outlined in Table 2.
Pneumococcal meningitis
Prognosis depends on the severity of both encephalitic
impairment and associated systemic signs. Mortality is high
(16–33%) with otoneurological sequelae (17–29%) [10].
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Table 2
Predisposing factors and signs of severity
Aetiologic agent Predisposing factors
Streptococcus Previous history of head injury, surgery at the 
pneumoniae base of the skull, meningitis, rhinorrhea, sudden 
onset, neurological signs, otitis, sinusitis or 
associated pneumopathy, asplenia, human 
immunodeficiency virus infection
Neisseria Possible epidemic, purpura
meningitidis
Listeria Immunodepression, signs of 
monocytogenes rhomboencephalitis, cloudy cerebrospinal fluid 
with mixed composition
Haemophilus Age <5 years, absence of vaccination. 
influenzae
Principal signs Purpura fulminans, deep coma (Glasgow coma 
of severity score <8), cardiorespiratory failureMeningococcal meningitis
In such cases severity is indicated by the infectious signs
of purpura fulminans (6–13% of meningococcal infections,
of which there is a 50% mortality) than to neurological
signs, which have a low mortality rate (3–10%) and rare
sequelae (6–10%) including deafness, impairment of
another cranial nerve, hydrocephalus and epilepsy.
Listeria meningitis
The prognosis is poor, with 33% mortality and 33% sequelae
including upper function, tonic and deglutination disorders.
Treatment
Antibiotic therapy
There is no justification for delaying antibiotic therapy
(Tables 3 and 4), because early treatment is associated with
better outcome in cases of meningococcal and pneumococ-
cal meningitis. Treatment must therefore be started imme-
diately after the lumbar puncture and the initial blood
culture, and sometimes before if the CSF examination has
been deferred (patient far from a hospital, decision to
perform a CT scan) and/or if the symptoms appear to be
fulminant (fever at 40°C, meningeal syndrome and worsen-
ing level of consciousness in <24h or purpura; Fig. 1) [23].
Neisseria meningitidis
N. meningitidis is sensitive to penicillins and third-genera-
tion cephalosporins. Amoxicillin (200mg/kg per day),
cefotaxime (200mg/kg per day), or ceftriaxone
(70–100mg/kg per day) can be used for 7–10 days [28].
Listeria monocytogenes
The reference treatment for L. monocytogenes is amoxicillin
(200mg/kg per day) plus gentamicin (6mg/kg per day),
which, despite the weak meningeal diffusion of these
compounds, is justified because of their in-vitro synergis-
tic effect and the frequency of initial bacteraemic forms.
Another excellent possibility, supported by its diffusion
into the CSF, is co-trimoxazole: 960mg every 12h intra-
venously for 2–3weeks [29].
Haemophilus influenzae
H. influenzae meningitis is treated by cefotaxime
(200mg/kg per day) or ceftriaxone (70–100mg/kg per day).
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Table 3 
Initial treatment of purulent meningitis with negative direct examination, absence of predisposing factors and signs of severity [1]
Antibiotic Posology (mg/kg per day) Administration route
Child >3 months Cefotaxime 200–300 Four infusions
or ceftriaxone 70–100* One or two intravenous injections
Adult Amoxicillin 200 Four to six infusions
or cefotaxime 200–300 Four infusions
or ceftriaxone 70–100 One or two intravenous injections
*Maximum 4g/day
Table 4
Initial treatment of purulent meningitis with negative direct examination, according to predisposing factors and/or signs of
severity [1]
Patient Suspected organisms Treatment (posology)
Child Neisseria meningitidis Amoxicillin or 3-GC
Streptococcus pneumoniae 3-GC + vancomycin
Haemophilus influenzae 40–60 mg/kg per day. Four infusions >1h or continuous infusion
(load: 15mg/kg) 3-GC
Adult Streptococcus pneumoniae Preference 3-GC
If suspicion of penicillin-resistant 3-GC + vancomycin 40–60mg/kg per day. Four infusions >1h or 
pneumococci and/or signs of severity continuous infusion (load: 15 mg/kg)
Listeria monocytogenes Amoxicillin is indispensable in association with gentamicin or co
trimoxazole
Neisseria meningitidis Amoxicillin or 3-GC
Child and adult Absence of predisposing factors Amoxicillin + 3-GC
and signs of severity
3-GC, cefotaxime or ceftriaxone (see Table 1 for posologies).Streptococcus pneumoniae
Antibiotic therapy for S. pneumoniae is confronted with two
difficulties: the virulence of the micro-organism and
increasing resistance to the antibiotics usually prescribed
for purulent community-acquired meningitis. The major
antibiotics that have the best in-vitro activity on PRP are
cefotaxime, ceftriaxone, vancomycin, amoxicillin and
imipenem. Rapid determination of the MIC for the above
b-lactams is indispensable in order to best adjust the treat-
ment. The therapy is administered by the intravenous
route for 10–14days and is prolonged in cases of slow
response and/or a strain with reduced sensitivity. The
choice of antibiotic therapy is governed by the age of the
patient, the presence of signs of severity and/or risk factors
for PRP [23,30,31].
In children under 3months of age or in adults with risk
factors for PRP and/or presenting with signs of severity,
initial treatment must include a third-generation
cephalosporin such as cefotaxime (300mg/kg per day in
four infusions) or ceftriaxone (70–100mg/kg per day in
one or two injections, maximum 4g/day), and vancomycin
(60mg/kg per day either in four infusions of at least 1h or
in continuous infusion with an initial load of 15mg/kg)
[32]. Re-evaluation is performed at 36–48h and is based
on the clinical data and lumbar puncture.
If the evolution is favourable, further treatment will
depend on the MIC of the cephalosporin that is used. If
the MIC is inferior to 0.5mg/l, one can discontinue the
vancomycin and possibly reduce the dosage of the third-
generation cephalosporin (to 200mg/kg per day) or pre-
scribe amoxicillin (150–200mg/kg per day) if the
amoxicillin MIC is inferior to 0.12mg/l.
If the third-generation cephalosporin MIC is superior or
equal to 0.5mg/l, initial treatment must be continued. In
case of clinical and/or microbiological failure, treatment
must be modified by taking into account the results of the
second lumbar puncture, the MIC of the antibiotics and the
concentration of vancomycin in the CSF [21,23]. The drug
combination should be decided with the microbiologist and
chosen among a list of antibiotics for which the MIC are
known: imipenem, meropenem, rifampin and fosfomycin.
The initial treatment for an adult without a risk factor for
PRP or signs of severity is cefotaxime (200–300mg/kg per
day in four infusions), but amoxicillin remains an option at
a dose of 200mg/kg per day in four to six infusions, espe-
cially in regions where the prevalence of PRP is low. Clin-
ical re-evaluation is performed at 36–48h. For subsequent
treatment, if the evolution is favourable and if the strain
has normal sensitivity to these b-lactams, one can reduce
the dose of the third-generation cephalosporin or pre-
scribe amoxicillin (150–200mg/kg per day). When the
MIC of the third-generation cephalosporin is superior or
equal to 0.5mg/l, lumbar puncture is indispensable to
confirm an improvement in the CSF; such improvement
mandates continuation of the initial treatment. In cases of
clinical and/or microbiological failure, the treatment must
be modified by adding vancomycin to the initial treatment
(see doses above).
It is recommended to treat H. influenzae and meningococ-
cal meningitis for 7–10 days, but longer periods of 10–21
days are required for other pathogens: 10–14 days for
S. pneumoniae; 14–21 days for L. monocytogenes and group B
streptococci; and 21 days for Gram-negative bacilli, except
for H. influenzae.
Empirical choice of an antibiotic therapy
When lumbar puncture is delayed or direct examination of
the CSF is not helpful, empiric treatment is essential. A
broad-spectrum cephalosporin (cefotaxime or ceftriaxone)
is recommended for most patients, combined with ampi-
cillin in children under 3 months and adults over 50 years
(two populations in which S. agalactiae and L. monocytogenes
are frequently found). In patients with recent head trauma
or who have undergone neurosurgery, the clinician must
choose a broad-spectrum antibiotic treatment that is active
on Gram-positive and Gram-negative bacteria, such as the
combination of ceftazidime and vancomycin. In immuno-
compromised patients (chemotherapy, corticotherapy,
haematologic tumours), treatment must include ampicillin
(for possible listeriosis) and a cephalosporin, such as cef-
tazidime, which is active on Gram-negative bacilli.
Intensive care
Given the number of cases of life-threatening secondary
or associated visceral impairment, it is important to treat
respiratory failure, septic shock, intracranial hypertension
or disseminated intravascular coagulation. As for the latter
syndrome, a recent study has demonstrated the interest of
administering concentrated Protein C for purpura fulmi-
nans in cases of meningococcemia.
Treatment of the portal of entry
Otorhinologic treatment of otitis and sinusitis is an emer-
gency that can be put off for a few days if the clinical evo-
lution during the first few days is favourable. It can include
atticomastoidectomy, exeresis of a cholesteatoma or sinus
drainage. Detection of traumatic osteodural breaches and
their treatment are not considered as emergencies.
Immunotherapy
Corticotherapy
The use of anti-inflammatory agents, particularly dexam-
ethasone, makes it possible to reduce local inflammatory
reactions that are responsible for cerebral oedema and
thereby reduce the morbidity and mortality in purulent
meningitis. Several recent studies [23,33,34], notably in
children, have investigated neurosensory sequelae and
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the initial phase of bacterial meningitis. These studies
have demonstrated a possible reduction in mortality that
has, however, only been found in open studies performed
in populations of patients whose clinical presentation was
immediately severe with treatment often delayed. A
reduction in auditory sequelae, even neuromotor seque-
lae, in children treated with dexamethasone (double-blind
studies), especially in children with H. influenzae purulent
meningitis, has been noted; there is probably a similar
effect for pneumococcal meningitis, but cannot be evalu-
ated from the available data for meningococcal meningitis.
In adults there is only partial information on the efficacy
of initial corticotherapy, but there are potential disadvan-
tages of corticosteroid use. Through the rapid sympto-
matic modifications that they can trigger, corticosteroids
can interfere with assessment of evolution and lead to pos-
sible errors in clinical interpretation. Consequently, they
must not be used for a meningitis that is insufficiently
documented. Complications due to corticotherapy when
used in this context are very rare. On the other hand, one
can observe a return of fever when corticosteroid treat-
ment is stopped. The use of dexamethasone in animal
models has demonstrated a reduction in the penetration of
certain antibiotics, including vancomycin, into the CSF.
This could create a problem for treatment with certain
antibiotics with relatively weak meningeal diffusion in
cases of PRP infection.
On the whole, the favourable benefit:risk ratio for early
corticoid therapy would advocate the prescription of dex-
amethasone at the beginning of treatment of purulent
meningitis in children when it is probably due to the usual
community bacteria. For adults, however, additional clini-
cal studies will be necessary to draw conclusions on this
point. The adults who could benefit the most are those
who present with a high bacterial concentration in the
CSF and signs of intracranial hypertension [35].
When it is used, corticotherapy must be instituted early. It
is usually administered a few minutes before the first dose
of antibiotic [ie, dexamethasone intravenously (0.6mg/kg
per day in two to four injections)]. The duration of treat-
ment is debatable, but a 2-day treatment would appear to
be as effective as a 4-day treatment. If dexamethasone is
chosen, it is better to associate it with rifampicin rather
than vancomycin in cases of PRP.
Antimediators
The use of agents that block the action of polynuclear
cells or cytokines has been promising in experimental
meningitis, but has yet to be validated in humans. A
recent clinical study would seem to have found an inter-
esting effect of a protein that increases bacterial perme-
ability (rBPI21) in 26 children aged from 1 to 18 years and
presenting with severe meningococcaemia.
Prophylaxis
Pneumococcal meningitis
Continuous cyclic chemoprophylaxis with penicillin G is
used in certain adults (following splenectomy, osteodural
breach victims), but is not based on well established data
[36]. The emergence of resistant strains should put this
practice into question.
Vaccination is recommended for patients at risk. It is debat-
able for patients aged over 65 years or under certain circum-
stances for elderly or handicapped patients living in groups.
Its efficacy has not been demonstrated, especially given the
poor vaccination response in groups at risk. Vaccination is
ineffective before the age of 2years and not advisable in
pregnant women. A booster vaccination is performed after
5years or earlier in immunocompromised patients.
Meningococcal meningitis
In France, a Public Health Service declaration is obligatory
once a case has been identified. Prophylaxis involves those
in contact with the patient before diagnosis (living under
the same roof in the 10 days before hospitalization, close
friends, immediate neighbours in class, cafeteria, room) and
after curative treatment, as well as clinical staff exposed to
air contamination (mouth-to-mouth resuscitation, intuba-
tion). It is extended to an entire school class if several cases
have occurred in the same class, and to an entire school if
three or more cases have occurred in different classes in less
than a month. Casual contacts (coworkers, other students
who were not close to the patient, health care personnel in
general) are not involved. Except for secondary cases, mea-
sures must be taken within 8 days of the diagnosis and are
organized by the family doctor (in household cases) or, in
group cases, by the Public Health Service and the doctor
responsible for the group. Contact subjects and contacts
from the same group as the patient must be informed about
the disease and the measures to be taken. Medical observa-
tion of the contact subjects must be undertaken for 2weeks
after the institution of prophylactic measures. Rhinopharyn-
geal disinfection and sampling are not useful. Suspension
from school or isolation of the contact subjects is not recom-
mended. Given the fragility of meningococcus, disinfection
or closure of an establishment, including a school, are mea-
sures that are unnecessary and unjustified.
Chemoprophylaxis consists of rifampicin per os for 2 days:
in adults, 600mg twice a day; in children aged 1 month to
12 years, 10mg/kg three times a day; in children aged
under 1month, 5mg/kg twice a day. The wearing of soft
contact lenses must be stopped during treatment due to
the risk of irreversible dyeing. Moreover, subjects taking
oral contraception must be given another contraceptive
solution due to the risk of enzymatic induction.
The contraindications are pregnancy, severe hepatic
disease, porphyrias and hypersensitivity to rifampicin. In
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adults, 3million IU twice a day; in children, 75000IU/kg
twice a day.
Vaccination (meningococcal vaccine A+C) is recom-
mended in addition to chemoprophylaxis, beginning at
the age of 3months in the case of meningococcus A and
from 1year of age in the case of meningococcus C. It can
also be offered to those who have stayed in a region with
an epidemic: peace corps workers and members of
medical expeditions in the sahel. Professional or academic
suspension of contact subjects and disinfection of
premises are not useful.
Haemophilus influenzae type B meningitis 
The probability of contracting meningitis is markedly
increased in children aged under 4years living in the same
domicile as an index case. Prophylaxis relies on the
administration of rifampicin (30mg/kg per day) for 4days
from the age of 1month. It provides an eradication rate of
approximately 95% for carriers of H. influenzae. The emer-
gence of type B strains that are resistant to rifampicin is
rare (0.2% in France). H. influenzae type B vaccination and
protective and immunogenic vaccines in very young chil-
dren have greatly modified the epidemiology of meningi-
tis in countries where these vaccines are used on a large
scale. In France, according to the National Reference
Center data, 635 strains of H. influenzae were isolated in
CSF between 1984 and 1992, 71 strains in 1993, and 34
strains in 1994.
Listeria monocytogenes meningitis
The prevention of listeriosis essentially depends on food
hygiene. This applies to pregnant women, immunocom-
promised subjects and the elderly.
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